首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

1705683

HIV臨床試驗市場（按階段、研究設計、發起人類型、適應症和地區分類）

HIV Clinical Trials Market, By Phase, By Study Design, By Sponsor Type, By Indication, By Geography, By Geography

出版日期: 2025年02月11日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年全球 HIV 臨床試驗市場規模為 15.7 億美元，到 2032 年將達到 23.6 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 6.0%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	15.7億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年複合年成長率：	6.00%	2032年價值預測	23.6億美元

數字。 HIV臨床試驗市場佔有率（%）（按地區，2025年）

全球愛滋病毒臨床試驗市場的成長是由世界各地為開發治療和預防愛滋病毒的有效治療方法和疫苗而進行的越來越多的臨床試驗所推動的。由於愛滋病患者數量的不斷增加，生物製藥公司和研究機構正在加大對愛滋病臨床研發活動的投入。此外，人們對臨床試驗的認知不斷提高以及私營和政府部門對其可用性的提高有助於擴大市場。然而，愛滋病毒臨床試驗的長期性和高成本可能會帶來挑戰。

市場動態

全球愛滋病毒臨床試驗市場的成長主要受到全球愛滋病毒感染者數量不斷增加導致對先進治療方案的需求不斷成長的推動。根據聯合國愛滋病規劃署的數據，截至2020年6月，全球約有3,800萬人感染愛滋病毒。廣泛的患者群體鼓勵製藥公司透過臨床研究積極投資愛滋病疫苗和藥物開發。世界衛生組織、比爾和梅琳達蓋茲基金會和國際藥品採購機制等組織增加對愛滋病毒臨床研究的私人和公共資助可能會推動市場成長。例如，2020年11月，美國過敏和感染疾病研究所為美國的愛滋病毒臨床研究提供了一筆大筆津貼。然而，臨床試驗的時間較長且成本較高，可能會阻礙市場成長。此外，圍繞病人安全的監管障礙和道德問題可能會阻礙愛滋病毒臨床試驗市場的成長。由於臨床研究成本低，中國和印度等新興經濟體很可能在不久的將來為市場相關人員創造豐厚的機會。

本研究的主要特點

本報告對全球愛滋病毒臨床試驗市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2024 年。

它還強調了各個領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。

它還涵蓋了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及吉利德科學公司、艾伯維公司、百時美施貴寶公司、葛蘭素史克公司、輝瑞公司、羅氏控股公司、賽諾菲公司、諾華公司、安斯泰來幫助製藥公司、勃林格格主要企業公司、Vertex Pharmaceticals Incorporated、Vanuman Incorporated、如工業公司採用和工業企業的主要競爭公司。

本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

全球愛滋病毒臨床試驗市場報告迎合了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過用於分析全球愛滋病臨床試驗市場的各種策略矩陣來更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1.57 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.00%	2032 Value Projection:	USD 2.36 Bn

Global HIV clinical trials market growth is driven by rising number of clinical studies conducted worldwide to develop effective therapies and vaccines for HIV treatment and prevention. Biopharmaceutical companies and research organizations are increasingly investing in HIV clinical research and development activities due to growing HIV patient population. Furthermore, increasing awareness regarding clinical trials and availability of government as well as private can aid the market expansion. However, long durations and high costs associated with HIV clinical studies can pose challenges.

Market Dynamics

Global HIV clinical trials market growth is primarily driven by growing need for advanced treatment options due to increasing prevalence of HIV infections worldwide. In June 2020, as per UNAIDS data, around 38 million people lived with HIV globally in 2020. This wide patient base encourages pharmaceutical players to invest aggressively in HIV vaccine and drug development through clinical research. Rising private and public funding for HIV clinical studies from organizations like WHO, Bill & Melinda Gates Foundation, and UNITAID can drive the market growth. For instance, in November 2020, the National Institute of Allergy and Infectious Diseases provided significant grants for HIV clinical studies in the U.S. However, long timeline and high costs associated with clinical trials can hamper the market growth. Moreover, regulatory hurdles and ethical issues pertaining to patient safety can hamper the growth of the HIV clinical trials market. Emerging nations like China and India with lower costs for clinical research could generate lucrative opportunities for market players in the near future.

Key Features of the Study

This report provides in-depth analysis of the global HIV clinical trials market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players like Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Sanofi S.A., Novartis AG, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Vertex Pharmaceuticals Incorporated, Amgen Inc., and Takeda Pharmaceutical Company Limited

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global HIV clinical trials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HIV clinical trials market

Market Segmentation

Phase Insights (Revenue, USD Bn, 2020 - 2032)
- Phase I
- Phase II
- Phase III
- Phase IV
- Preclinical
Study Design Insights (Revenue, USD Bn, 2020 - 2032)
- Interventional Studies
- Observational Studies
- Expanded Access Studies
Sponsor Type Insights (Revenue, USD Bn, 2020 - 2032)
- Pharmaceutical & Biotechnology Companies
- Academic Research Institutes
- Government & Private Research Organizations
- Contract Research Organizations (CROs)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- HIV-1
- HIV-2
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Gilead Sciences, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Roche Holding AG
- Sanofi S.A.
- Novartis AG
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Takeda Pharmaceutical Company Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global HIV Clinical Trials Market, By Phase
- Global HIV Clinical Trials Market, By Study Design
- Global HIV Clinical Trials Market, By Sponsor Type
- Global HIV Clinical Trials Market, By Indication
- Global HIV Clinical Trials Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends

4. Global HIV Clinical Trials Market, By Phase, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global HIV Clinical Trials Market, By Study Design, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Interventional Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Observational Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Expanded Access Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global HIV Clinical Trials Market, By Sponsor Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pharmaceutical & Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Academic Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Government & Private Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global HIV Clinical Trials Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
HIV-1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
HIV-2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global HIV Clinical Trials Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Vertex Pharmaceuticals Incorporated
Amgen Inc.
Takeda Pharmaceutical Company Limited